Last reviewed 2026-04-22 · How we verify

aMIL

aMIL is a personalized neoantigen vaccine that trains the immune system to recognize and attack cancer cells expressing patient-specific tumor mutations.

aMIL is a personalized neoantigen vaccine that trains the immune system to recognize and attack cancer cells expressing patient-specific tumor mutations. Used for Lymphoma (personalized neoantigen therapy).

At a glance

Mechanism of action

aMIL (autologous Mutation-specific Immunotherapy for Lymphoma) is an individualized therapeutic cancer vaccine designed to stimulate T-cell responses against neoantigens derived from somatic mutations in a patient's own tumor. The vaccine is manufactured by sequencing the patient's tumor, identifying non-synonymous mutations, and creating a personalized immunogen that primes cytotoxic T lymphocytes to target cancer cells bearing these unique mutations.

Approved indications

• Lymphoma (personalized neoantigen therapy)

Common side effects

• Injection site reactions
• Fatigue
• Fever

Key clinical trials

• Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation (PHASE1)
• Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma (PHASE1, PHASE2)
• Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma (PHASE2)
• Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.